Recordati Industria Chimica e Farmaceutica

RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 19 th February 2024 – Within the Recordati's share buy-back program communicated to the market on 29th September 2023 and initiated on 2nd October 2023 , as per authorization granted by the Shareholders' Meeting held on 21st April 2023, with the object of the servicing of current and future stock option / performance shares plans in favour of the Recordati Group's management or share-based incentive plans that might be approved by the Company in the future, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/EU, on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made from 12th to 16th February 2024 in Recordati ordinary shares (ISIN IT0003828271) are as follows:

SUMMARY OF PURCHASE TRANSACTIONS
Date Type of		Quantity	Weighted average price	Exchange
	Transaction		(Euro)
12/02/2024	Purchase	3,335	50.4812	MTA
13/02/2024	Purchase	10,076	50.2152	MTA
14/02/2024	Purchase	1,829	50.3458	MTA
15/02/2024	Purchase	2,148	50.5256	MTA
16/02/2024	Purchase	972	50.8534	MTA
TOTAL		18,360	50.3466

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 16th February 2024, the Company held no. 2,808,789 treasury shares which amount to 1.343% of the current share capital.

Recordati (Reuters RECI.MI, Bloomberg REC IM) is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271) uniquely structured to bring treatment across specialty and primary care, consumer healthcare, and rare diseases. We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege. We want to support people in unlocking the full potential of their life. We have fully integrated operations across research & development, chemical and finished product manufacturing through to commercialisation and licensing. Established in 1926, Recordati operates in approximately 150 countries across EMEA, Americas and APAC regions. At the end of 2022, Recordati employed more than 4,300 people and consolidated revenue of € 1,853.3 million. For more information, please visit www.recordati.com.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Tel. +39 02 487871 Fax +39 02 40073747 www.recordati.com

Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l.

Investor Relations Eugenia Litz +44 7824 394 750 e-mail: [email protected] Investor Relations Lucia Abbatantuoni +39 337 1025645 e-mail: [email protected] Media Relations Brunswick: Barbara Scalchi / Andrea Mormandi +39 02 9288 6200 e-mail: [email protected]